Erythropoietin-Secreting Tumors
The tumors most commonly associated with erythropoietin (EPO) secretion are renal cell carcinoma, cerebellar hemangioblastoma, hepatocellular carcinoma (hepatoma), and uterine leiomyomas.
Primary EPO-Secreting Tumors
Renal Cell Carcinoma
Renal adenocarcinoma is the classic EPO-secreting malignancy, with 1-5% of cases presenting with secondary polycythemia 1. The tumor cells themselves—specifically those of tubular epithelial origin—constitutively produce EPO, as demonstrated by in situ hybridization showing EPO mRNA within the malignant cells 1. This production is constitutive and not induced by hypoxia or other stimuli 2. The EPO gene shows no rearrangement in these tumors; rather, the malignant cells aberrantly express normal EPO 2, 1.
Cerebellar Hemangioblastoma
Capillary hemangioblastomas are well-documented EPO-producing tumors that frequently cause secondary polycythemia 3. Immunohistochemical studies demonstrate EPO within scattered stromal cells among the tumor architecture 3. These tumors harbor cells that both contain and likely produce EPO or substances with similar antigenic properties 3.
Hepatocellular Carcinoma
Hepatomas are recognized as EPO-secreting tumors causing paraneoplastic erythrocytosis 2. The liver normally produces EPO during fetal development, and hepatocellular carcinomas can reactivate this embryonic function.
Uterine Leiomyomas
Although benign, uterine fibroids can produce EPO and cause secondary erythrocytosis in rare cases 4, 5. This condition, termed myomatous erythrocytosis syndrome (MES), shows a positive correlation between tumor size and degree of erythrocytosis 5. Surgical resection results in normalization of hemoglobin levels 4.
Additional Tumors with EPO Production
Wilms tumors, hepatoblastomas, and various pediatric solid tumors (neuroblastomas, Ewing's sarcoma, medulloblastomas, astrocytomas, ependymomas, and rhabdomyosarcomas) express both EPO and functional EPO receptors 6. In these tumors, EPO expression is hypoxia-inducible and appears to promote tumor cell survival through antiapoptotic pathways and angiogenesis rather than causing systemic erythrocytosis 6.
Clinical Recognition
Key Diagnostic Features:
- Elevated hemoglobin and hematocrit disproportionate to clinical status
- Elevated serum EPO levels (measured by radioimmunoassay)
- Absence of other causes of polycythemia (hypoxia, smoking, chronic lung disease, renal disease)
- Normalization of blood counts following tumor resection
Important Caveats:
The presence of polycythemia with a solid tumor should prompt measurement of serum EPO levels. However, not all tumors expressing EPO cause systemic erythrocytosis—pediatric tumors express EPO primarily for autocrine/paracrine effects on tumor survival and angiogenesis rather than erythropoiesis 6.
Tumor resection remains the definitive treatment for paraneoplastic polycythemia, with resolution of erythrocytosis confirming the diagnosis 4, 2, 1.